Previous 10 | Next 10 |
Pacira BioSciences, Inc. (PCRX) Q4 2020 Earnings Conference Call February 25, 2021 08:30 ET Company Participants Susan Mesco - Head of Investor Relations David Stack - Chairman & Chief Executive Officer Charlie Reinhart - Chief Financial Officer Ron Ellis - Senior Vice President Conferenc...
Pacira BioSciences (PCRX): Q4 Non-GAAP EPS of $0.87 beats by $0.06; GAAP EPS of $0.32 misses by $0.13.Revenue of $131M (+7.0% Y/Y) in-line.Press Release For further details see: Pacira BioSciences EPS beats by $0.06, revenue in-line
— Reports record full-year 2020 revenue of $429.6 million — — Anesthesia-driven regional approaches expanding and driving strong EXPAREL growth — — Conference call today at 8:30 a.m. ET — PARSIPPANY, N.J., Feb. 25, 2021...
Pacira BioSciences (NASDAQ:PCRX) is scheduled to announce Q4 earnings results on Thursday, February 25th, before market open.The consensus EPS Estimate is $0.81 (+44.6% Y/Y) and the consensus Revenue Estimate is $130.91M (+6.9% Y/Y).Over the last 2 years, PCRX has beaten EPS estimates 88% of ...
PARSIPPANY, N.J., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2020 financial results before the open of the U.S. markets on Thursday, February 25, 2021. Following the release, the...
Pacira BioSciences (PCRX) reported January preliminary unaudited net product sales of EXPAREL and iovera° of $34.9M and $1.1M, respectively. EXPAREL average daily sales stood at 108% of the prior year."Importantly, we continue to see the successful migration of complex elective surg...
PARSIPPANY, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the leading provider of innovative non-opioid pain management options, today reported preliminary unaudited net product sales of EXPAREL ® (bupivacaine liposome injectable suspension) and i...
PARSIPPANY, N.J., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the leading provider of innovative non-opioid pain management options, today announced that the company will lead an equity investment in GeneQuine Biotherapeutics GmbH. Under the terms of the agree...
SVB Leerink has downgraded Pacira BioSciences (PCRX) to Market Perform from Outperform citing competitive pressure on its lead product EXPAREL® (bupivacaine liposome injectable suspension).However, the price target was raised to $75 from $63 based on the results from a ‘physi...
Announcing the preliminary unaudited financial results, Pacira BioSciences (PCRX) reports $429.6M of net revenue for 2020, a 2.0% YoY growth, compared to ~24.8% YoY growth in 2019.The biggest revenue generator, long-acting local analgesic, EXPAREL recorded net product sales of $413....
News, Short Squeeze, Breakout and More Instantly...
Pacira BioSciences Inc. Company Name:
PCRX Stock Symbol:
NASDAQ Market:
Pacira BioSciences Inc. Website:
TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results after the close of the U.S. markets on Tuesday July 30, 2024. Following the release, the company will host a live conference call and webc...
-- Proposed Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment System Rule extends separate payment from ambulatory surgical centers to include the hospital outpatient environment – -- Rule implements the NOPAIN Act, signed into law as part of the Cons...
A look at the top 10 most actives in the United States Ocean Power Technologies Inc. (OPTT) rose 86.1% to $0.514 on volume of 587,366,807 shares NVIDIA Corporation (NVDA) fell 1.3% to $122.67 on volume of 214,038,378 shares Tesla Inc. (TSLA) rose 10.2% to $231.26 on volume of 201,850,947 ...